Surgical Science completes the acquisition of Simbionix

Surgical Science Sweden AB (publ) announced on July 28, 2021 that a conditional agreement to acquire all shares outstanding of Simbionix USA Corp. (“Simbionix”) had been entered into. Simbionix works with simulation for training of surgeons and other medical specialists within a broad number of areas, such as for robotic surgery. The company has approximately 120 employees, of which approximately 100 employees are based in Israel and approximately 20 are based in the US.

Surgical Science Sweden AB (publ) today, after all conditions precedent have been fulfilled, has completed the acquisition of all shares of Simbionix USA Corp. and the subsidiary Simbionix, Ltd and thus controls 100% of the shares in the two companies. Both companies will be consolidated into Surgical Science upon closing of the acquisition.

Please refer to press releases dated July 28 and 29 and August 16, 2021 for further details.

Gothenburg, Sweden, August 24, 2021
Surgical Science Sweden AB (publ)

The press release is available in the attachment or via
https://surgicalscience.com/aktien/pressmeddelanden/

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Medical education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based laparoscopic and endoscopic training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the operating room. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Surgical Science is headquartered in Gothenburg, Sweden and present in Stockholm, Sweden, Tel Aviv, Israel as well as in Seattle, Washington, in the US. Through sales offices in the US, France, China and UAE as well as a global network of distributors, Surgical Science maintains a presence in most markets around the world. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank (Telephone: 08-463 83 00; E-mail: certifiedadviser@penser.se).

Surgical Science completes the acquisition of Simbionix